Lycorine

• Description :

  Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a Kd value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription[2]. Lycorine is also a melanoma vasculogenic inhibitor[3]. Lycorine can be used for the study of prostate cancer and metabolic diseases[2].

• UNSPSC :

  12352005

• Hazard Statement :

  H301

• Target :

  Apoptosis; Bacterial; Fatty Acid Synthase (FASN) ; Virus Protease

• Type :

  Natural Products

• Related Pathways :

  Anti-infection; Apoptosis; Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/lycorine.html

• Concentration :

  10mM

• Purity :

  99.98

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O[C@@H]1[C@@H](O)C=C(CC2)[C@@]3([H])N2CC4=C([C@@]31[H])C=C(OCO5)C5=C4

• Molecular Formula :

  C16H17NO4

• Molecular Weight :

  287.31

• Precautions :

  H301

• References & Citations :

  [1]Hu M, et al.Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.Oncotarget. 2015 Jun 20;6 (17) :15348-61.|[2]Zu-Guo Zheng, et al. Discovery of a Potent SCAP Degrader That Ameliorates HFD-induced Obesity, Hyperlipidemia and Insulin Resistance via an Autophagy-Independent Lysosomal Pathway. Autophagy. 2020 May 20;1-22.|[3][1].Liu, R. et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment cell & melanoma research 25, 630-638, doi:10.1111/j.1755-148X.2012.01036.x (2012) .

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  No Development Reported

• Citation 01 :

  Ann Hematol. 2023 May;102 (5) :1073-1086.|Antiviral Res. 2024 Jul 2:228:105955.|Eur J Pharmacol. 2023 Dec 15:961:176162.|Int J Mol Med. 2022 Dec;50 (6) :145.|Int J Mol Sci. 2025 Jun 3;26 (11) :5358.|J Exp Clin Cancer Res. 2022 Mar 30;41 (1) :116.|Microorganisms. 2022 Oct 21;10 (10) :2089.|Mol Med Rep. 2024 Mar;29 (3) :48.|Oncol Lett. 2021 Nov;22 (5) :781.|Pharmacol Res. 2022 Jan:175:105985.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2022 Jan.|bioRxiv. 2024 Feb 6:2024.02.06.579103.|Cancers (Basel) . 2025 Feb 20;17 (5) :718.|Patent. US20230014181.|Preprints. 2024 Nov.

• CAS Number :

  [476-28-8]